HALDRONE
LOE ApproachingNDAORALTABLET
Approved
Apr 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HALDRONE is an oral small-molecule tablet approved by Eli Lilly in 1961 for an undisclosed indication. The specific mechanism of action and therapeutic area remain proprietary or historical information not provided in current datasets.
LOE Approaching
Product is approaching loss of exclusivity with minimal commercial data available; brand teams should anticipate transition planning and resource reallocation to newer assets.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings and LOE-approaching status indicate this is a legacy product with limited hiring momentum. Career growth on HALDRONE is constrained; professionals should consider this a maintenance role rather than a springboard opportunity.
Brand ManagerField Sales
Worked on HALDRONE at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.